Related Experiment Videos
Systemic therapy
1The Johns Hopkins Oncology Center, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21231-1000, USA. awolff@jhmi.edu
Abstract:
Our knowledge base on systemic therapy for breast cancer continues to expand, including further information regarding hormonal prevention in high-risk women, beneficial effects of tamoxifen in noninvasive disease, an update on primary systemic therapy, and optimization of adjuvant strategies, including data on adjuvant chemoendocrine regimens. The proper evaluation of high-dose strategies has been jeopardized by a serious episode of scientific misconduct. New data are also available on palliative options, bisphosphonates, antibody therapies, and novel targets. Data continue to evolve on the role and optimal schedules of taxanes in early-stage and advanced breast cancer. These and other important recent findings are discussed in this review article.
Insights
This review covers advances in breast cancer systemic therapy, including hormonal prevention, tamoxifen benefits, and adjuvant strategies. It also discusses palliative options, antibody therapies, and taxane use in early and advanced stages.
Area of Science:
- Oncology
- Pharmacology
- Medical Research
Background:
- The field of systemic therapy for breast cancer is rapidly evolving.
- Key areas of advancement include hormonal prevention, noninvasive disease treatment, and adjuvant therapy optimization.
- Emerging data also impact palliative care and novel therapeutic targets.
Purpose of the Study:
- To provide a comprehensive review of recent findings in breast cancer systemic therapy.
- To discuss updates on hormonal prevention, tamoxifen efficacy, and adjuvant chemoendocrine regimens.
- To highlight new data on palliative options, bisphosphonates, antibody therapies, novel targets, and taxane utilization.
Main Methods:
- Review of current scientific literature and recent clinical trial data.
- Synthesis of information on hormonal prevention, primary systemic therapy, and adjuvant strategies.
- Analysis of data concerning palliative care, bisphosphonates, antibody therapies, and taxanes.
Main Results:
- Expanded knowledge on hormonal prevention for high-risk women and tamoxifen's role in noninvasive disease.
- Updated insights into primary systemic therapy and optimization of adjuvant chemoendocrine regimens.
- New data on palliative options, bisphosphonates, antibody therapies, novel targets, and evolving taxane schedules.
Conclusions:
- Systemic therapy for breast cancer encompasses a wide range of evolving strategies.
- Continued research is crucial for optimizing treatment outcomes across all stages of breast cancer.
- Recent findings offer improved options for prevention, treatment, and palliative care.